OBJECTIVE: The U1-70-kd RNP is a prominent target of autoimmunity in connective tissue diseases. In this study, we explored whether its endogenous ligand, U1 RNA, mediates a proimmune signal and may be immunogenic. METHODS: We assayed the proliferation of control and MyD88-knockout splenocytes in response to in vitro-synthesized U1 RNA, and measured interleukin-6 (IL-6) and IL-8 secretion induced by U1 RNA in a human cell line competent for signaling through Toll-like receptor 3 (TLR-3) and TLR-5. RESULTS: Treatment with U1 RNA or with poly(I-C), a known agonist of TLR-3, induced approximately twice as much control splenocyte proliferation as did treatment with RNase-digested U1 RNA. Proliferation in response to either poly(I-C) or U1 RNA by MyD88-knockout splenocytes was similarly attenuated. Similar to poly(I-C), U1 RNA induced significant secretion of both IL-6 and IL-8 from a TLR-3-expressing human cell line; in contrast, the TLR-5 agonist flagellin induced predominantly IL-8 secretion. Pretreatment of U1 RNA with RNase abolished IL-6 and IL-8 secretion. CONCLUSION: U1 RNA is capable of inducing manifestations consistent with TLR-3 activation. The ability of U1 RNA (which has a substantial double-stranded secondary structure) to activate TLR-3 may contribute to the immunogenicity of the U1-70-kd autoantigen. Stimulation of innate immunity by native RNA molecules with a double-stranded secondary structure may help explain the high prevalence of autoimmunity to RNA binding proteins.
OBJECTIVE: The U1-70-kd RNP is a prominent target of autoimmunity in connective tissue diseases. In this study, we explored whether its endogenous ligand, U1 RNA, mediates a proimmune signal and may be immunogenic. METHODS: We assayed the proliferation of control and MyD88-knockout splenocytes in response to in vitro-synthesized U1 RNA, and measured interleukin-6 (IL-6) and IL-8 secretion induced by U1 RNA in a human cell line competent for signaling through Toll-like receptor 3 (TLR-3) and TLR-5. RESULTS: Treatment with U1 RNA or with poly(I-C), a known agonist of TLR-3, induced approximately twice as much control splenocyte proliferation as did treatment with RNase-digested U1 RNA. Proliferation in response to either poly(I-C) or U1 RNA by MyD88-knockout splenocytes was similarly attenuated. Similar to poly(I-C), U1 RNA induced significant secretion of both IL-6 and IL-8 from a TLR-3-expressing human cell line; in contrast, the TLR-5 agonist flagellin induced predominantly IL-8 secretion. Pretreatment of U1 RNA with RNase abolished IL-6 and IL-8 secretion. CONCLUSION: U1 RNA is capable of inducing manifestations consistent with TLR-3 activation. The ability of U1 RNA (which has a substantial double-stranded secondary structure) to activate TLR-3 may contribute to the immunogenicity of the U1-70-kd autoantigen. Stimulation of innate immunity by native RNA molecules with a double-stranded secondary structure may help explain the high prevalence of autoimmunity to RNA binding proteins.
Authors: M Muzio; D Bosisio; N Polentarutti; G D'amico; A Stoppacciaro; R Mancinelli; C van't Veer; G Penton-Rol; L P Ruco; P Allavena; A Mantovani Journal: J Immunol Date: 2000-06-01 Impact factor: 5.422
Authors: W Lawley; A Doherty; S Denniss; D Chauhan; G Pruijn; W J van Venrooij; J Lunec; K Herbert Journal: Rheumatology (Oxford) Date: 2000-03 Impact factor: 7.580
Authors: Eric L Greidinger; Mark F Foecking; Kim R Schäfermeyer; Craig W Bailey; Shannon L Primm; David R Lee; Robert W Hoffman Journal: J Immunol Date: 2002-09-15 Impact factor: 5.422
Authors: Jamie J Bernard; Christopher Cowing-Zitron; Teruaki Nakatsuji; Beda Muehleisen; Jun Muto; Andrew W Borkowski; Laisel Martinez; Eric L Greidinger; Benjamin D Yu; Richard L Gallo Journal: Nat Med Date: 2012-07-08 Impact factor: 53.440
Authors: J A Somarelli; A Mesa; R Rodriguez; R Avellan; L Martinez; Y J Zang; E L Greidinger; R J Herrera Journal: Lupus Date: 2011-03 Impact factor: 2.911
Authors: Donna L Thibault; Alvina D Chu; Kareem L Graham; Imelda Balboni; Lowen Y Lee; Cassidy Kohlmoos; Angela Landrigan; John P Higgins; Robert Tibshirani; Paul J Utz Journal: J Clin Invest Date: 2008-04 Impact factor: 14.808
Authors: Donna L Thibault; Kareem L Graham; Lowen Y Lee; Imelda Balboni; Paul J Hertzog; Paul J Utz Journal: Arthritis Res Ther Date: 2009-07-22 Impact factor: 5.156